This episode examines three FDA regulatory decisions establishing frameworks for AI-enabled medical imaging and contrast delivery infrastructure. Topics include pre-market approval of Claire, an optical coherence tomography device for intraoperative breast cancer margin assessment with continuous AI learning authorization; Breakthrough Device Designation for Cognitas, a generative radiology AI entering expedited review; and 510(k) clearance for MEDRAD MRXperion contrast injector compatibility with seven Tesla MRI scanners and bidirectional scanner communication. The briefing details trial performance data, regulatory pathway structures, and infrastructure integration specifications across surgical and diagnostic imaging environments.
